The Experts below are selected from a list of 54969 Experts worldwide ranked by ideXlab platform
Gerardo Hernandezoliva - One of the best experts on this subject based on the ideXlab platform.
-
comparison of short term treatment regimen of ciprofloxacin versus long term treatment regimens of trimethoprim Sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections a randomized multicentre open label prospective study
Journal of Antimicrobial Chemotherapy, 2004Co-Authors: Jose Luis Arredondogarcia, Ricardo Figueroadamian, Alejandro Rosas, Arturo Jauregui, Mauricio Corral, Alexis Costa, Roberto Mauricio Merlos, Antonio Riosfabra, Carlos F Amabilecuevas, Gerardo HernandezolivaAbstract:Objective: To compare the bacteriological and clinical efficacy of three treatments for uncomplicated cystitis in ambulatory pre-menopausal women: ciprofloxacin 250 mg orally twice daily for 3 days, trimethoprim/Sulfamethoxazole 160/800 mg orally twice daily for 7 days, and norfloxacin 400 mg orally twice daily for 7 days. Materials and methods: A total of 455 women were randomly assigned to three treatment groups: 151 received ciprofloxacin, 150 received trimethoprim/Sulfamethoxazole, and 154 received norfloxacin. Bacteriological cure and clinical resolution were evaluated 5-9 days and 4-6 weeks after completion of treatment. Results: There was no significant difference among the three treatment groups: overall efficacy ranged from 78.5% for the trimethoprim/Sulfamethoxazole group, to 84.5% for the ciprofloxacin group. The highest overall incidence of drug-related adverse effects occurred in the trimethoprim/Sulfamethoxazole patients. Conclusions: These data indicate that a 3 day treatment with ciprofloxacin is at least as clinically and bacteriologically effective as 7 day treatments with trimethoprim/Sulfamethoxazole and norfloxacin for uncomplicated lower urinary tract infections.
Roger Echols - One of the best experts on this subject based on the ideXlab platform.
-
a randomized trial of short course ciprofloxacin ofloxacin or trimethoprim Sulfamethoxazole for the treatment of acute urinary tract infection in women
The American Journal of Medicine, 1999Co-Authors: James M Mccarty, George A Richard, Werner Huck, Richard M Tucker, Robert Tosiello, Michael Shan, Allen Heyd, Roger EcholsAbstract:Abstract PURPOSE: Bladder infections are very common in otherwise healthy women, and short-course antimicrobial treatment appears effective for many episodes of cystitis. This study reports the results of short-course ciprofloxacin, ofloxacin, and trimethoprim/Sulfamethoxazole therapy. PATIENTS AND METHODS: We performed a randomized, double-blind study of the efficacy and safety of a 3-day course of oral ciprofloxacin 100 mg twice daily, ofloxacin 200 mg twice daily, or trimethoprim/Sulfamethoxazole 160/800 mg twice daily in women with acute, uncomplicated, symptomatic lower urinary tract infection. RESULTS: A total of 866 patients were enrolled, of whom 688 (79%) were evaluated for the efficacy of treatment (229 treated with ciprofloxacin, 228 treated with trimethoprim/Sulfamethoxazole, and 231 treated with ofloxacin). The most frequent reason for exclusion was the failure to identify a pretreatment pathogen. The most commonly isolated pathogen was Escherichia coli (81%). Eradication of the pretreatment pathogen at the end of therapy occurred in 94% of ciprofloxacin, 93% of trimethoprim/Sulfamethoxazole, and 97% of ofloxacin-treated patients. At follow-up evaluation at 4 to 6 weeks, recurrence rates (relapse or reinfection) were 11% in the ciprofloxacin, 16% in the trimethoprim/Sulfamethoxazole, and 13% in the ofloxacin treatment group. Clinical success at the end of therapy was 93% in the ciprofloxacin, 95% in the trimethoprim/Sulfamethoxazole, and 96% in the ofloxacin treatment groups. The frequency of all adverse events was 31% for ciprofloxacin, 41% for trimethoprim/Sulfamethoxazole, and 39% for ofloxacin-treated patients ( P = 0.03). Premature discontinuation of study drug due to an adverse event was more common in trimethoprim/Sulfamethoxazole-treated patients (n = 9) compared with those given ciprofloxacin (n = 2) or ofloxacin (n = 1; P = 0.02). CONCLUSION: Ciprofloxacin, ofloxacin, and trimethoprim/Sulfamethoxazole had similar efficacy when given for 3 days to treat acute, symptomatic, uncomplicated lower urinary tract infection in women.
Jose Luis Arredondogarcia - One of the best experts on this subject based on the ideXlab platform.
-
comparison of short term treatment regimen of ciprofloxacin versus long term treatment regimens of trimethoprim Sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections a randomized multicentre open label prospective study
Journal of Antimicrobial Chemotherapy, 2004Co-Authors: Jose Luis Arredondogarcia, Ricardo Figueroadamian, Alejandro Rosas, Arturo Jauregui, Mauricio Corral, Alexis Costa, Roberto Mauricio Merlos, Antonio Riosfabra, Carlos F Amabilecuevas, Gerardo HernandezolivaAbstract:Objective: To compare the bacteriological and clinical efficacy of three treatments for uncomplicated cystitis in ambulatory pre-menopausal women: ciprofloxacin 250 mg orally twice daily for 3 days, trimethoprim/Sulfamethoxazole 160/800 mg orally twice daily for 7 days, and norfloxacin 400 mg orally twice daily for 7 days. Materials and methods: A total of 455 women were randomly assigned to three treatment groups: 151 received ciprofloxacin, 150 received trimethoprim/Sulfamethoxazole, and 154 received norfloxacin. Bacteriological cure and clinical resolution were evaluated 5-9 days and 4-6 weeks after completion of treatment. Results: There was no significant difference among the three treatment groups: overall efficacy ranged from 78.5% for the trimethoprim/Sulfamethoxazole group, to 84.5% for the ciprofloxacin group. The highest overall incidence of drug-related adverse effects occurred in the trimethoprim/Sulfamethoxazole patients. Conclusions: These data indicate that a 3 day treatment with ciprofloxacin is at least as clinically and bacteriologically effective as 7 day treatments with trimethoprim/Sulfamethoxazole and norfloxacin for uncomplicated lower urinary tract infections.
Charles M. Bark - One of the best experts on this subject based on the ideXlab platform.
-
Sulfamethoxazole Susceptibility of Mycobacterium tuberculosis Isolates from HIV-Infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis
Antimicrobial agents and chemotherapy, 2015Co-Authors: Sam Ogwang, Caryn E. Good, Brenda Okware, Mary Nsereko, Michael R. Jacobs, W. Henry Boom, Charles M. BarkAbstract:Additional drugs are needed for the treatment of multidrug-resistant tuberculosis (TB). Sulfamethoxazole has been shown to have in vitro activity against Mycobacterium tuberculosis; however, there is concern about resistance given the widespread use of trimethoprim-Sulfamethoxazole prophylaxis among HIV-infected patients in sub-Saharan Africa. Thirty-eight of 40 Mycobacterium tuberculosis isolates (95%) from pretreatment sputum samples from Ugandan adults with pulmonary TB, including HIV-infected patients taking trimethoprim-Sulfamethoxazole prophylaxis, were susceptible with MICs of ≤38.4 μg/ml.
Didier Raoult - One of the best experts on this subject based on the ideXlab platform.
-
Acquired Resistance to Trimethoprim- Sulfamethoxazole during Whipple Disease and Expression of the Causative Target Gene
2016Co-Authors: Nawal Bakkali, Florence Fenollar, Silpak Biswas, Jeanmarc Rolain, Didier RaoultAbstract:Background. Whipple disease is a chronic infection caused by Tropheryma whipplei. Trimethoprim-Sulfamethoxazole is recommended for treatment of Whipple disease but is associated with treatment failure. T. whipplei is resistant in vitro to trimethoprim, because the gene targeted by this agent is missing. Methods. Apatient experienced clinical failure during treatment with trimethoprim-Sulfamethoxazole. The gene encoding the enzyme putatively believed to be dihydropteroate synthase (DHPS), the target of Sulfamethoxazole, was amplified and sequenced for 20 T. whipplei strains from our laboratory and for isolates recovered from a case patient at the time of diagnosis and the time of treatment failure. An Escherichia coli knockout strain for this gene was complemented with the sequences from a susceptible strain and from isolates recovered from the case patient. Susceptibilities of complemented E. coli to Sulfamethoxazole were tested. Results. The target gene was identified among genes encoding a unique trifunctional enzyme in which DHPS is combined with the 2 preceding enzymes of the folate biosynthesis pathway. Changes in the amino acid sequence of putative DHPS were detected in the case patient. Gene complementation showed that the gene encoding putative DHPS restored the folate biosynthesis pathway and susceptibility to Sulfamethoxazole, whereas themutated sequence was associated with Sulfamethoxazole resistance. Conclusions. Antibiotic susceptibility of fastidious bacteria such asT. whipplei can be evaluated bymeans of gen
-
acquired resistance to trimethoprim Sulfamethoxazole during whipple disease and expression of the causative target gene
The Journal of Infectious Diseases, 2008Co-Authors: Nawal Bakkali, Florence Fenollar, Silpak Biswas, Jeanmarc Rolain, Didier RaoultAbstract:Background. Whipple disease is a chronic infection caused by Tropheryma whipplei. Trimethoprim-Sulfamethoxazole is recommended for treatment of Whipple disease but is associated with treatment failure. T. whipplei is resistant in vitro to trimethoprim, because the gene targeted by this agent is missing. Methods. A patient experienced clinical failure during treatment with trimethoprim-Sulfamethoxazole. The gene encoding the enzyme putatively believed to be dihydropteroate synthase (DHPS), the target of Sulfamethoxazole, was amplified and sequenced for 20 T. whipplei strains from our laboratory and for isolates recovered from a case patient at the time of diagnosis and the time of treatment failure. An Escherichia coli knockout strain for this gene was complemented with the sequences from a susceptible strain and from isolates recovered from the case patient. Susceptibilities of complemented E. coli to Sulfamethoxazole were tested. Results. The target gene was identified among genes encoding a unique trifunctional enzyme in which DHPS is combined with the 2 preceding enzymes of the folate biosynthesis pathway. Changes in the amino acid sequence of putative DHPS were detected in the case patient. Gene complementation showed that the gene encoding putative DHPS restored the folate biosynthesis pathway and susceptibility to Sulfamethoxazole, whereas the mutated sequence was associated with Sulfamethoxazole resistance. Conclusions. Antibiotic susceptibility of fastidious bacteria such as T. whipplei can be evaluated by means of gene complementation techniques. Mutations in the target gene of Sulfamethoxazole appear during treatment.
